MX2023015440A - Compuesto de sulfoximina y uso del mismo. - Google Patents
Compuesto de sulfoximina y uso del mismo.Info
- Publication number
- MX2023015440A MX2023015440A MX2023015440A MX2023015440A MX2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A MX 2023015440 A MX2023015440 A MX 2023015440A
- Authority
- MX
- Mexico
- Prior art keywords
- sulfoximine compound
- compound
- sulfoximine
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- -1 Sulfoximine compound Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110694497 | 2021-06-22 | ||
| CN202210002094 | 2022-01-04 | ||
| CN202210665753 | 2022-06-13 | ||
| PCT/CN2022/100435 WO2022268119A1 (zh) | 2021-06-22 | 2022-06-22 | 亚磺酰亚胺类化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015440A true MX2023015440A (es) | 2024-04-29 |
Family
ID=84545187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015440A MX2023015440A (es) | 2021-06-22 | 2022-06-22 | Compuesto de sulfoximina y uso del mismo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240376093A1 (enExample) |
| EP (1) | EP4361138A4 (enExample) |
| JP (1) | JP2024526156A (enExample) |
| KR (1) | KR20240024906A (enExample) |
| CN (1) | CN117500796B (enExample) |
| AU (1) | AU2022298616A1 (enExample) |
| BR (1) | BR112023026964A2 (enExample) |
| CA (1) | CA3223641A1 (enExample) |
| IL (1) | IL309572A (enExample) |
| MX (1) | MX2023015440A (enExample) |
| TW (1) | TWI825800B (enExample) |
| WO (1) | WO2022268119A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120239699A (zh) * | 2022-12-22 | 2025-07-01 | 祐森健恒生物医药（上海）有限公司 | 一种吡啶多取代化合物的盐型、晶型及其制备方法 |
| WO2025186427A1 (en) * | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) * | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| CN111936486B (zh) * | 2018-03-22 | 2023-09-22 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
| JP7631193B2 (ja) * | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| CN213366611U (zh) * | 2018-11-05 | 2021-06-04 | 深圳市优行新能源有限公司 | 光伏组件 |
| SG11202108162SA (en) * | 2019-01-30 | 2021-08-30 | Bristol Myers Squibb Co | Amide-disubstituted pyridine or pyridazine compounds |
| AU2021254764A1 (en) * | 2020-04-14 | 2022-11-03 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| KR20230004771A (ko) * | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
| TW202227430A (zh) * | 2020-11-17 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
-
2022
- 2022-06-22 CA CA3223641A patent/CA3223641A1/en active Pending
- 2022-06-22 US US18/573,074 patent/US20240376093A1/en active Pending
- 2022-06-22 EP EP22827611.9A patent/EP4361138A4/en active Pending
- 2022-06-22 CN CN202280043560.8A patent/CN117500796B/zh active Active
- 2022-06-22 AU AU2022298616A patent/AU2022298616A1/en active Pending
- 2022-06-22 TW TW111123283A patent/TWI825800B/zh active
- 2022-06-22 MX MX2023015440A patent/MX2023015440A/es unknown
- 2022-06-22 WO PCT/CN2022/100435 patent/WO2022268119A1/zh not_active Ceased
- 2022-06-22 IL IL309572A patent/IL309572A/en unknown
- 2022-06-22 BR BR112023026964A patent/BR112023026964A2/pt unknown
- 2022-06-22 JP JP2023578894A patent/JP2024526156A/ja active Pending
- 2022-06-22 KR KR1020247001056A patent/KR20240024906A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117500796A (zh) | 2024-02-02 |
| US20240376093A1 (en) | 2024-11-14 |
| BR112023026964A2 (pt) | 2024-03-12 |
| WO2022268119A1 (zh) | 2022-12-29 |
| EP4361138A4 (en) | 2025-05-21 |
| IL309572A (en) | 2024-02-01 |
| CN117500796B (zh) | 2026-03-27 |
| CA3223641A1 (en) | 2022-12-29 |
| TW202315869A (zh) | 2023-04-16 |
| KR20240024906A (ko) | 2024-02-26 |
| EP4361138A1 (en) | 2024-05-01 |
| AU2022298616A1 (en) | 2024-01-18 |
| TWI825800B (zh) | 2023-12-11 |
| JP2024526156A (ja) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015419A2 (es) | Compuesto de péptido corto de prolina modificado con anillo y uso del mismo | |
| AR119672A1 (es) | Inhibidor de 15-pgdh | |
| AR115949A1 (es) | Compuestos heterocíclicos | |
| NI202000092A (es) | Compuestos | |
| AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX2025011216A (es) | Compuesto de pirimidopirano sustituido con heterocíclico y uso del mismo | |
| CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
| MX2024008987A (es) | Derivado de heteroaril-pireno sustituido por anillo puenteado, y uso del mismo. | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| ECSP21000990A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) | |
| MX2024012930A (es) | Derivado de ester de ciclopentanol sustituido con pirazol y uso del mismo | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| MX2023015440A (es) | Compuesto de sulfoximina y uso del mismo. | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| CO2024003094A2 (es) | Compuesto imidazocíclico y aplicación del mismo | |
| CL2022002817A1 (es) | Inhibidores de replicación del virus de inmunodeficiencia humana | |
| AR121598A1 (es) | Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano | |
| CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
| CL2023000313A1 (es) | Forma sólida de un compuesto | |
| AR110770A1 (es) | Moduladores del canal de potasio | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| DOP2011000154A (es) | 3-aminociclopentancarboxamidas | |
| MX2021009261A (es) | Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. | |
| MX2024004551A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana. | |
| CL2022001511A1 (es) | Procesos e intermediario para la preparación de oxetan-2-ilmetanamina |